Abstract
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 microg of the hemagglutinin (HA) of influenza A (H3N2 and H1N1) and B virus or a recombinant vaccine (rHAO) containing 15, 45, or 135 microg of each HA, reactogenicity was minor. Among patients with similar prevaccination titers, 40% given 45 microg and 60% given 135 microg of rHAO developed an increase in influenza A/H3 neutralizing antibody levels; there were no increases in 4 given TIV. For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine.
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Viral / blood
-
Baculoviridae / genetics
-
Dose-Response Relationship, Immunologic
-
Double-Blind Method
-
Female
-
Hemagglutinins, Viral / genetics
-
Hemagglutinins, Viral / immunology
-
Humans
-
Influenza A Virus, H1N1 Subtype / immunology
-
Influenza A Virus, H3N2 Subtype / immunology
-
Influenza B virus / immunology
-
Influenza Vaccines / adverse effects*
-
Influenza Vaccines / immunology*
-
Lymphoma, B-Cell / immunology
-
Male
-
Middle Aged
-
Neutralization Tests
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
-
Viral Proteins / genetics
-
Viral Proteins / immunology
Substances
-
Antibodies, Viral
-
Hemagglutinins, Viral
-
Influenza Vaccines
-
Vaccines, Synthetic
-
Viral Proteins
-
hemagglutinin fusogenic peptide, influenza virus